To determine whether the mutational landscape of individual tumours correlated with tumour phenotype, we quantified the immune cell infiltrate by labelling sections with antibodies against CD45 (all immune cells), CD3 (T-cells) and CD68 (macrophages) and measured the proportion of proliferating cells (EdU+) in all sequenced tumours (Fig. 5a–d; Supplementary Fig. 4a, b, Supplementary Table 1 and Supplementary Data 1). The gene discussed is PTPRC; the disease is neoplasm.